165 results on '"Sorigue M"'
Search Results
2. Difference in CD5 and CD10 expression according to anatomic site
3. FDG-PET/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma
4. Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review
5. Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma
6. Systematic review of staging bone marrow involvement in B cell lymphoma by flow cytometry
7. RITUXIMAB-BENDAMUSTINE IN THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A RETROSPECTIVE STUDY OF THE GELCAB GROUP
8. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients >= 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
9. FDG‐PET/CT‐GUIDED REBIOPSY MAY FIND CLINICALLY UNSUSPICIOUS TRANSFORMATION OF AN INDOLENT LYMPHOMA AT THE POINT OF DIAGNOSIS OR RELAPSE
10. Female patients with follicular lymphoma have a better prognosis if primary remission lasts over 24 months
11. Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia
12. Oral anticoagulation in patients with active cancer and atrial fibrillation: current challenges
13. Flow Cytometry in the Differential Diagnosis of CD10-Positive Nodal Lymphomas
14. Precision medicine in follicular lymphoma: Focus on predictive biomarkers
15. FMODexpression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study
16. Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies
17. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
18. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
19. QUANTIFICATION OF FMOD (FIBROMODULIN) IN WHOLE BLOOD FOR THE DIAGNOSIS OF LYMPHOPROLIFERATIVE SYNDROMES OF PHENOTYPE BOUNDARY BETWEEN CLL AND NON-CLL
20. CLINICAL AND MOLECULAR CHARACTERIZATION OF A SERIES OF PATIENTS WITH PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASMS ANS SPLANCHNIC THROMBOSIS
21. m7FLIPI and targeted sequencing in high-risk follicular lymphoma
22. Incidence of solid cancer in patients with follicular lymphoma
23. ANALYSIS OF THE IGH HYBRIDIZATION PATTERN, IN PLASMA CELLS OF PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA, WITH IGH-FGFR3 DUAL-COLOR, DUAL-FUSION AND IGH DUAL-COLOR BREAK-APART PROBE
24. DIFFERENCES BETWEEN CD10-POSITIVE FOLICULAR LYMPHOMA AND HIGH GRADE B-CELL LYMPHOMA BY FLOW CYTOMETRY
25. Recent landmark studies in follicular lymphoma
26. Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era
27. RESULTS OF AUTOLOGOUS HEMATOPOIETIC PROGENITOR TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS WITH LYMPHOMA: EXPERIENCE OF A CENTER
28. Interactions between direct anticoagulants and chemotherapy
29. Anticoagulation for atrial fibrillation in patients with active cancer
30. Risk of secondary haematological malignancies in patients with follicular lymphoma:an analysis of 1028 patients treated in the rituximab era
31. Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review
32. Current prognostic and predictive factors in follicular lymphoma
33. Expression of CD43 in chronic lymphoproliferative leukemias
34. Treatment of localized-stage follicular lymphoma
35. Phenotypic Characterization of Trisomy 12 Monoclonal B-Cell Lymphocytosis
36. Difference in CD5 and CD10 expression according to anatomic site
37. A Case of CD138-/CD19+/CD4+IgD Plasma Cell Leukemia
38. The clinical dilemma of grade 3 follicular lymphoma
39. CYTOGENETIC ALTERATIONS IN THE MOMENT OF RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (LAM) WITH NORMAL KARYOTYPE, INTERNAL DUPLICATION IN TANDEM OF THE GENE FLT3 (DT-FLT3) AND NPM1WT IN DIAGNOSIS
40. REFRACTARITY TO IMMUNOTHERAPY OR IMMUNOCHIMIOTERAPY IN LYMPHOMA OF THE MARGINAL ZONE
41. RESCUE TREATMENT IN PATIENTS WITH LYMPHOMA B DIFFUSE LARGE CELL (LBDCG) AND ELDERLY NON-CANDIDATES FOR AUTOLOGOUS TRANSPLANTATION OF PROGENITORS HAEMATOPOIECTIC (TAPH): EXPERIENCE OF A CENTER
42. DECREASE OF THE ERYTHROPOIETIC RESPONSE IN THE ANEMIA OF ANOREXIA NERVOSA
43. RISK OF SECONDARY HEMATOLOGICAL MALIGNANCY IN PATIENTS WITH FOLLICULAR LYMPHOMA.
44. Moving forward with [ 18 F]FDG PET/CT in low tumor burden follicular lymphoma.
45. Follow-up in patients with lymphoma: a call for an evidence-based approach.
46. Front-line and second-line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis.
47. Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice.
48. Real-world Data: MCL2 Protocol Demonstrates Excellent Treatment Results Among Patients With Mantle Cell Lymphoma Not Fulfilling the Original Trial Inclusion Criteria.
49. Estimating the Lifetime Treatment Burden of Patients With Follicular Lymphoma: A Retrospective Study Using Real-World Multicenter Data.
50. Diagnosis of erythroid dysplasia by flow cytometry: a review.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.